Dinah Weismann

Dinah Weismann

Company: Alcediag

Job title: Chief Executive Officer & Chief Scientific Officer

Seminars:

Panel Discussion: The Future Possibilities of RNA Editing 4:40 pm

Read more

day: Day Two

RNA Editing for Personalized Diagnostics in Neuropsychiatry 1:00 pm

Exploring how Alcediag develops RNA editing blood biomarkers powered by artificial intelligence in Mental health and neurosciences, inflammatory disease and oncology Discovering EDIT-B, EDIT-B is the first blood test based on RNA editing biomarkers to be introduced in psychiatry where diagnoses are only based on clinical evaluations Highlighting the efficacy of EDIT-B, it differentiates unipolar…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.